Condition: Glioma · Glioblastoma · Recurrent Glioma · Sponsor: Kailin Yang, MD, PhD
Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or progressed after treatment, and 2) find out what the highest dose of sitagliptin is appropriate to give when combined with bevacizumab.
This description comes directly from the study's public registry record.
Kailin Yang, MD, PhD · +1 319 356 3630 · kailin-yang@uiowa.edu
Always discuss trial participation with your own doctor first.
| University of Iowa Health Care | Iowa City, Iowa, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07541781